Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment.
Case-mix adjustment
Functional status
Health-service research
Multilevel analysis
Patient-reported outcome measures
Prostate neoplasms
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
13
05
2019
accepted:
19
01
2020
pubmed:
11
2
2020
medline:
6
8
2021
entrez:
11
2
2020
Statut:
ppublish
Résumé
The self-reported functional status (sr-FS) of prostate cancer (PCa) patients varies substantially between patients and health-care providers before treatment. Information about this issue is important for evaluating comparisons between health-care providers and to assist in treatment decision-making. There have been few reports on correlates of pretherapeutic sr-FS. The objective of the article, therefore, is to describe clinical and sociodemographic correlates of pretherapeutic sr-FS, based on a subset of the TrueNTH Global Registry, a prospective cohort study. A total of 3094 PCa patients receiving local treatment in 44 PCa centers in Germany were recruited between July 2016 and April 2018. Multilevel regression models were applied to predict five pretherapeutic sr-FS (EPIC-26) scores based on clinical characteristics (standard set suggested by the International Consortium for Health Outcomes Measurement), sociodemographic characteristics, and center characteristics. Impaired pretherapeutic sr-FS tended to be associated with lower educational level and poorer disease characteristics-except for "urinary incontinence" which was only associated with age. Notably, age was a risk factor ("urinary incontinence," "urinary irritative/obstructive," "sexual") as well as a protective factor ("hormonal") for pretherapeutic sr-FS. Pretherapeutic sr-FS varies little across centers. Pretherapeutic sr-FS varies by clinical patient characteristics and age as well as by socioeconomic status. The findings point out the benefit of collecting and considering socioeconomic information in addition to clinical and demographic patient characteristics for treatment decision-making and fair comparisons between health-care providers.
Identifiants
pubmed: 32040715
doi: 10.1007/s00345-020-03097-z
pii: 10.1007/s00345-020-03097-z
pmc: PMC7858203
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-36Références
Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF (2015) The evolution of self-reported urinary and sexual dysfunction over the last two decades: implications for comparative effectiveness research. Eur Urol 67(6):1019–1025. https://doi.org/10.1016/j.eururo.2014.08.035
doi: 10.1016/j.eururo.2014.08.035
pubmed: 25174325
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822. https://doi.org/10.1001/jama.2013.879
doi: 10.1001/jama.2013.879
pubmed: 23443445
Klinkhammer-Schalke M, Koller M, Steinger B, Ehret C, Ernst B, Wyatt JC, Hofstadter F, Lorenz W, Regensburg Qo LSG (2012) Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer. Br J Cancer 106(5):826–838. https://doi.org/10.1038/bjc.2012.4
doi: 10.1038/bjc.2012.4
pubmed: 22315052
pmcid: 3305975
Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. https://doi.org/10.1200/JCO.2015.63.0830
doi: 10.1200/JCO.2015.63.0830
pubmed: 26644527
Hartz A, He T, Strope S, Cutler DR, Andriole G, Dechet C (2013) Surgeon variation in patient quality of life after radical prostatectomy. J Urol 189(4):1295–1301. https://doi.org/10.1016/j.juro.2012.10.118
doi: 10.1016/j.juro.2012.10.118
pubmed: 23123548
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, Bonaventure A, Valkov M, Johnson CJ, Esteve J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England) 391(10125):1023–1075. https://doi.org/10.1016/s0140-6736(17)33326-3
doi: 10.1016/s0140-6736(17)33326-3
pmcid: 5879496
Zaider T, Manne S, Nelson C, Mulhall J, Kissane D (2012) Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer. J Sex Mede 9(10):2724–2732. https://doi.org/10.1111/j.1743-6109.2012.02897.x
doi: 10.1111/j.1743-6109.2012.02897.x
Lucas SM, Kim TK, Ghani KR, Miller DC, Linsell S, Starr J, Peabody JO, Hurley P, Montie J, Cher ML (2017) Establishment of a web-based system for collection of patient-reported outcomes after radical prostatectomy in a statewide quality improvement collaborative. Urology 107:96–102. https://doi.org/10.1016/j.urology.2017.04.058
doi: 10.1016/j.urology.2017.04.058
pubmed: 28652160
Beyer B, Mandel P, Michl U, Pompe RS, Veleva V, Steuber T, Huland H, Graefen M, Tilki D (2016) Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. World J Urol 34(8):1101–1105. https://doi.org/10.1007/s00345-015-1758-2
doi: 10.1007/s00345-015-1758-2
pubmed: 26757719
Jacobs BL, Lopa SH, Yabes JG, Nelson JB, Barnato AE, Degenholtz HB (2016) Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population. Cancer 122(20):3199–3206. https://doi.org/10.1002/cncr.30184
doi: 10.1002/cncr.30184
pubmed: 27379732
pmcid: 5048507
Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EAS, Guedea F, Cvancarova M, Fosså SD (2014) Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment. Clin Genitourin Cancer 12(4):e117–e125. https://doi.org/10.1016/j.clgc.2013.12.007
doi: 10.1016/j.clgc.2013.12.007
pubmed: 24524968
pmcid: 5021779
Marmot M (2005) Social determinants of health inequalities. Lancet 365(9464):1099–1104. https://doi.org/10.1016/s0140-6736(05)74234-3
doi: 10.1016/s0140-6736(05)74234-3
pubmed: 15781105
Kowalski C, Hein R, Carl G, Feick G, Oesterle A, Hinkel A, Steiner T, Brock M, Kaftan B, Borowitz R, Zantl N, Heidenreich A, Neisius A, Darr C, Bolenz C, Beyer B, Pfitzenmaier J, Brehmer B, Fichtner J, Haben B, Wesselmann S, Dieng S (submitted) Implementing a multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: design and progress report.
Evans SM, Millar JL, Moore CM, Lewis JD, Huland H, Sampurno F, Connor SE, Villanti P, Litwin MS (2017) Cohort profile: the TrueNTH Global Registry—an international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open 7(11):e017006. https://doi.org/10.1136/bmjopen-2017-017006
doi: 10.1136/bmjopen-2017-017006
pubmed: 29183925
pmcid: 5719323
Kowalski C, Ferencz J, Albers P, Fichtner J, Wiegel T, Feick G, Wesselmann S (2016) Quality assessment in prostate cancer centers certified by the German Cancer Society. World J Urol 34(5):665–672. https://doi.org/10.1007/s00345-015-1688-z
doi: 10.1007/s00345-015-1688-z
pubmed: 26391484
Martin NE, Massey L, Stowell C, Bangma C, Briganti A, Bill-Axelson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67(3):460–467. https://doi.org/10.1016/j.eururo.2014.08.075
doi: 10.1016/j.eururo.2014.08.075
pubmed: 25234359
Sibert NT, Dieng S, Oesterle A, Feick G, Carl G, Steiner T, Minner J, Roghmann F, Kaftan B, Zengerling F, Hinkel A, Beyer B, Heidenreich A, Harke N, Brehmer B, Pfitzenmaier J, Fichtner J, Neisius A, Hammerer P, Wesselmann S, Kowalski C (2019) Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer. World J Urol. https://doi.org/10.1007/s00345-019-02949-7
doi: 10.1007/s00345-019-02949-7
pubmed: 31552467
Sanda MG, Wei JT, Litwin MS (2002) Scoring instructions for the expanded prostate cancer index composite schort form (EPIC-26). The Universityy of Michigan, Ann Arbor
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2018) [Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0].
Core Team R (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
Bates D, Mächler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw. https://doi.org/10.18637/jss.v067.i01
doi: 10.18637/jss.v067.i01
Venables WN, Ripley BD (2002) Modern applied statistics with S, 4th edn. Springer, New York
doi: 10.1007/978-0-387-21706-2
Resnick MJ, Barocas DA, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF (2014) Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment. Cancer 120(8):1263–1271. https://doi.org/10.1002/cncr.28563
doi: 10.1002/cncr.28563
pubmed: 24510400
pmcid: 4930672
Rezaei N, Azadi A, Pakzad R (2018) Prevalence of andropause among Iranian men and its relationship with quality of life. Aging Male. https://doi.org/10.1080/13685538.2018.1490951
doi: 10.1080/13685538.2018.1490951
pubmed: 30081749
Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019) Interpretation of Domain Scores on the EPIC: How Does the Domain Score Translate into Functional Outcomes? The Journal of urology:101097ju0000000000000392. doi:10.1097/ju.0000000000000392
Barocas DA, Alvarez J, Resnick MJ et al (2017) Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 317(11):1126–1140. https://doi.org/10.1001/jama.2017.1704
doi: 10.1001/jama.2017.1704
pubmed: 28324093
pmcid: 5782813
Herden J, Ansmann L, Ernstmann N, Schnell D, Weissbac L (2016) The treatment of localized prostate cancer in everyday practice in Germany. Dtsch Arztebl Int 113(19):329–336. https://doi.org/10.3238/arztebl.2016.0329
doi: 10.3238/arztebl.2016.0329
pubmed: 27232362
pmcid: 4904528
Klein J, Ovd K (2015) Socioeconomic inequalities in prostate cancer survival: a review of the evidence and explanatory factors. Soc Sci Med. https://doi.org/10.1016/j.socscimed.2015.07.006
doi: 10.1016/j.socscimed.2015.07.006
pubmed: 26281022